title: Estradiol gel 0.1% relieves vasomotor symptoms independent of age, ovarian status, or uterine status.
abstract: OBJECTIVE
  Data from a pivotal efficacy trial have been reanalyzed to explore the impact of age, uterine status, and ovarian status on the efficacy of estradiol gel 0.1% (Divigel) for the treatment of moderate to severe vasomotor symptoms associated with menopause.
  
  
  METHODS
  Post hoc analyses were performed on data from a phase III clinical trial of estradiol gel 0.1%. These analyses explored the effects of age (<50, 50-59, ≥60 y) and uterine and ovarian status (intact or absent) on the change from baseline to week 12 in the frequency and severity of moderate to severe vasomotor symptoms. The effects of age, uterine status, and ovarian status were investigated for each individual dose (1.0, 0.5, and 0.25 g) of estradiol gel 0.1% (separately and pooled) compared with those of placebo.
  
  
  RESULTS
  Treatment with any dose of estradiol gel 0.1% reduced both the frequency and severity of moderate to severe vasomotor symptoms from baseline regardless of age, uterine status, or ovarian status. Women 50 years or older, regardless of uterine or ovarian status, treated with estradiol gel 0.1% showed improvement in vasomotor symptoms compared with women given matched placebo. No interactions were detected between estradiol gel 0.1% treatment and age, uterine status, or ovarian status on vasomotor symptom frequency or severity.
  
  
  CONCLUSIONS
  Estradiol gel 0.1% treatment numerically decreased the frequency and severity of vasomotor symptoms in healthy, postmenopausal women independent of age, uterine status, or ovarian status. To our knowledge, these data are the first to directly explore the effects of age, hysterectomy, and oophorectomy on the efficacy of transdermal estrogen therapy.
authors: Hawthorne OB/GYN Associates, Winston-Salem, NC 27103, USA. rhedrick@hawthorneresearch.net
authors: Richard E
authors: RE
authors: Hedrick
authors: Ronald T
authors: RT
authors: Ackerman
authors: William D
authors: WD
authors: Koltun
authors: Mark B
authors: MB
authors: Halvorsen
mesh_terms: D000367:Age Factors; D017326:Clinical Trials, Phase III as Topic; D004958:Estradiol / Q000008:administration & dosage* / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D005260:Female; D019584:Hot Flashes / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008593:Menopause / Q000502:physiology*; D008875:Middle Aged; D010053:Ovary; D016032:Randomized Controlled Trials as Topic; D014599:Uterus; D014666:Vasomotor System / Q000187:drug effects / Q000503:physiopathology*
chemical_list: D004958:Estradiol